PharmaCyte Biotech Inc. Common Stock (PMCB)
Stock · NASDAQ · Health Care
$0.3402as of 10/16/2026
Price chart
Active signals
PMCB Signal Track Record
How signals performed across all stocks →What PMCB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +1.1% | 53% | September 3, 2026 |
| Bollinger Band Breakdown | 27 | +0.3% | 52% | September 10, 2026 |
| Bollinger Band Breakout | 16 | -6.8% | 25% | May 14, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -7.7% | 23% | June 16, 2026 |
| Any 20-session window (baseline) | -2.2% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PMCB
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancr…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 2
- Website
- pharmacyte.com/
Fundamentals
- 1-day range
- $0.3408$0.3743
- Market cap
- $6.34M
- P/E (trailing)
- —
- P/E (forward)
- -0.92
- EPS (trailing)
- $-1.90
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 206.6K
How PharmaCyte Biotech Inc. Common Stock Makes Money
Where the revenue actually goes — FY2013 annual results
Source: 10-K filed Jul 29, 2013 · via SEC EDGAR / Finnhub
PharmaCyte Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
- BCABBioAtla Inc. Common Stock$1.36▲ 4.62%Market cap $5.53MP/E —$1.07$71.5
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- CLDICalidi Biotherapeutics Inc. Common Stock$0.837▼ 3.79%Market cap $4.38MP/E —$0.82$27.84
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
| BCAB BioAtla Inc. Common Stock | $5.53M | — | $1.36 | ▲ 4.62% | $1.07$71.5 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| CLDI Calidi Biotherapeutics Inc. Common Stock | $4.38M | — | $0.837 | ▼ 3.79% | $0.82$27.84 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 1.10M
- Total value held
- $693.2K
- Institutional holders
- 31
- Unknown519.7K
- Unknown195.7K
- Unknown56.5K
- Unknown52.4K
- Unknown51.5K
- Unknown37.5K
- Unknown35.6K
- Unknown27.0K
- Unknown24.7K
- Unknown22.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
PMCB Listed Among 12 Health Care Stocks Moving After-Market
PharmaCyte Biotech was included in a list of 12 health care stocks that saw price movement during Friday's after-market session. The stock is currently trading within its 52-week range of $0.35 to $1.51. This inclusion highlights recent trading activity in the healthcare sector, though specific details on the magnitude of the move are not provided in the available data.
PMCB Listed Among 12 Health Care Stocks Moving After-Market. PharmaCyte Biotech was included in a list of 12 health care stocks that saw price movement during Friday's after-market session. The stock is currently trading within its 52-week range of $0.35 to $1.51. This inclusion highlights recent trading activity in the healthcare sector, though specific details on the magnitude of the move are not provided in the available data.